Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | JAK1 | P23458 | 3/20 | 0.49 |
| ▸ | TYK2 | P29597 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299147 | 0.90 | JAK2 (0.51) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL12102727 | 0.89 | JAK2 (0.49) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL3265360 | 0.89 | JAK2 (0.49) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL13521286 | 0.88 | JAK2 (0.50) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL1298782 | 0.88 | JAK2 (0.52) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL13521304 | 0.88 | JAK2 (0.50) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL1299128 | 0.88 | JAK2 (0.49) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL1299226 | 0.88 | JAK2 (0.51) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL12105318 | 0.88 | JAK2 (0.48) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL12102307 | 0.87 | JAK2 (0.54) | JAK2CYP3A4CYP2C8CYP2C9JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885CYP3A4 3372/4885CYP2C8 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.